NASDAQ$AXGN

Axogen Inc. · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Reported an increase in revenue and improved gross margin, driven by procedure volume improvements and hospital adaptations.

Axogen reported a 3% increase in net revenue to $34.5 million for the second quarter of 2022 compared to the second quarter of 2021. Excluding Avive revenue from the prior year, revenue increased by 9%. The gross margin improved to 81.8%, and the adjusted net loss decreased to $2.6 million, or $0.06 per share.

  • Net revenue increased by 3% to $34.5 million compared to Q2 2021.
  • Excluding Avive revenue, net revenue increased by 9% compared to Q2 2021.
  • Gross margin was 81.8% compared to 78.9% in Q2 2021.
  • Adjusted net loss was $2.6 million, or $0.06 per share, compared to $3.7 million, or $0.09 per share, in Q2 2021.

Headline financials

Total Revenue

$34.5M

Previous: $33.6M+2.6%
EPS (adj)

-$0.06

Previous: -$0.09+33.3%
Capital Expenditures

-$9.09M

Previous: -$10.9M+16.8%
Free Cash Flow

-$16.8M

Previous: -$18.8M+10.6%
Net Income

-$7.74M

Previous: -$7.9M+2.0%
Operating Income

-$7.92M

Previous: -$7.15M-10.8%
Gross Profit

$28.2M

Previous: $26.5M+6.4%
Cash & Equivalents

$11.8M

Previous: $53.1M-77.7%
Total Assets

$196M

Previous: $211M-6.9%
Stock-Based Comp

$4.91M

Previous: $3.81M+29.0%

Revenue & EPS history

Axogen · Revenue · Quarterly

$34.5M

Q2 2022+2.6%vs Q2 2021
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Forward guidance

The Company continues to expect 2022 revenue will be in the range of $135.0 million to $142.0 million. Full-year 2022 gross margin is expected to be above 80%.

Tailwinds

  • 2022 revenue is expected to be in the range of $135.0 million to $142.0 million.
  • Revenue represents approximately 10% to 15% growth over 2021 revenue excluding the impact of $4.1 million of Avive revenue in 2021.
  • Full-year 2022 gross margin is expected to be above 80%.
  • Positive top-line results from the RECON Phase 3 Study of Avance.
  • Completed enrollment of 86 subjects in the comparative phase study of REPOSE.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+1.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+6.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+39.1%

Q2 2024

Best reaction

-27.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+9.9%+2.6%
Q4 2025-6.6%-10.3%-8.8%
Q3 2025+22.8%+28.6%+58.5%
Q1 2025-23.2%-33.6%-33.4%
Q4 2024+11.7%+11.1%+5.4%
Q3 2024-17.4%-13.4%-2.7%
Q2 2024+39.1%+42.2%+64.4%
Q1 2024-11.7%-11.1%+4.1%
Q4 2023-14.4%-17.4%-26.7%
Q3 2023+37.4%+27.7%+88.8%
Q2 2023-20.8%-27.9%-27.0%
Q1 2023-1.8%-4.6%-0.8%
Q4 2022+11.6%+9.2%+37.8%
Q3 2022+19.0%+21.4%+0.6%
Q2 2022+2.1%+1.2%-10.7%
Q1 2022+23.4%+17.7%+16.8%
Q4 2021+8.0%+27.1%+6.2%
Q3 2021-13.3%-6.0%-37.3%
Q2 2021-2.5%-9.5%-12.5%
Q1 2021+14.9%+13.3%-1.2%
Q4 2020+3.6%+7.0%-7.7%
Q3 2020+3.4%+10.4%+18.0%
Q2 2020+0.3%-2.3%-1.7%
Q1 2020-14.7%-9.6%+10.9%
Q4 2019-17.6%-15.8%-36.3%
Q3 2019+12.4%+13.3%+23.8%
Q2 2019-27.3%-21.8%-5.5%
Q1 2019-2.1%-5.4%-15.7%
Q4 2018+1.6%+6.7%+13.4%
Q3 2018+9.3%+12.8%-1.3%
Q2 2018-12.6%-13.1%-2.4%
Q1 2018-5.1%+5.2%+14.2%
Q4 2017+8.8%+4.5%+17.0%
Q3 2017+10.7%+15.3%+28.5%
Q2 2017-4.8%-6.4%+14.7%
Q1 2017+3.3%+3.7%+25.6%
Q4 2016-0.5%-0.5%-5.2%
Q3 2016-1.7%-10.9%-7.4%
Q2 2016+25.1%+26.2%+32.9%
Q1 2016-0.4%
Q4 2015-4.7%
Q3 2015+17.3%
Q2 2015+5.4%
Q1 2015+3.1%
Q4 2014+3.8%
Q3 2014+5.5%
Q2 2014+1.3%
Q1 2014+1.6%
Q4 2013-8.5%
Q3 2013+1.8%
Q2 2013-0.3%
Q1 2013-14.7%
Q4 2012+4.5%
Q3 2012-1.8%
Q2 2012+18.2%
Q1 2012+0.3%
Q4 2011-4.5%
Q3 2011-14.8%
Q2 2010+0.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010-6.8%
Q3 2010+9.7%
Q1 2010-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro